Medical Treatments and Therapies

This slide set discusses use of the Ryan White Care Act (RWCA) to provide treatment of hepatitis C coinfection in persons living with HIV. It presents an overview of viral hepatitis, the basics of hepatitis C compared with hepatitis A and B, acute and chronic infection, prevention, HCV treatment and side effects of treatment, treatment decisions,, barriers to treatment, and increasing access to treatment through the RWCA.

This report presents guidelines for diagnosing, evaluating, and treating hepatitis C in persons incarcerated in Federal government prisons. It explains the transmission of hepatitis C virus (HCV), acute HCV infection and its treatment; chronic HCV infection; and a stepwise approach for detecting, evaluating, and treating chronic HCV infection. It discusses the direct-acting antiviral agents for treatment of chronic HCV infection that were FDA approved in May 2011, and their use, the indications and contraindications for triple therapy, managing side effects, and monitoring treatment response.

This poster states three important facts people should know about hepatitis C: it's a leading cause of liver cancer, millions of Americans have it, but don't know it, and treatments can eliminate the virus. The poster advises individuals to talk to their doctor about getting tested. The poster is also available in a smaller size, 26" x 36", at http://www.cdc.gov/knowmorehepatitis/media/pdfs/poster-facts24x36.pdf.

This poster states three important facts people should know about hepatitis C: it's a leading cause of liver cancer, millions of Americans have it, but don't know it, and treatments can eliminate the virus. The poster advises individuals to talk to their doctor about getting tested. The poster is also available in a smaller size, 8.5" x 11", at http://www.cdc.gov/knowmorehepatitis/Media/PDFs/Poster-Facts.pdf.

This internet file (web page) provides lessons on co-infection of HIV and hepatitis C. It discusses treatment; responder relapsers, partial responders, and null responders; experimental treatment; preventing cellular infection; viral enzyme target; immune therapies; and prevention. It includes two video clips, one with a hepatitis C patient, who relates her story, and the other with a doctor explains the importance of knowing about HCV for HIV infected individuals.

This internet electronic file discusses side effects of antiretroviral therapy for persons with HIV. The file provides information in table form on the most common adverse events for each of the five types of antiretroviral drugs.

This information sheet presents facts about viral hepatitis in tabular format. It discusses hepatitis A, B, and C. It lists statistics; routes of transmission; persons at risk; incubation period; symptoms of acute infection; the likelihood of symptomatic acute infection; the potential for chronic infection; the severity; serologic tests for acute and chronic infection; screening recommendations for chronic infection; treatment; vaccination recommendations and schedule, if any; and testing recommendations.

This pamphlet is a guideline to pharmacists on the use of antiretroviral drugs for the treatment of HIV. It discusses the important role of pharmacists in helping patients and clinicians with antiretroviral therapy (ART) considering the changes in treatment options, toxicities and side effects of ART, development of resistance, and problems of adherence.

This report updates previous US Public Health Service recommendations for the management of health-care personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management have not changed, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated.